外用糖皮质激素处方的人群队列研究
基于法国EGB数据库(覆盖约90%人群的1/97随机样本),2011—2015年共662 531人记录,其中220 345人(33.3%)至少一次被处方外用糖皮质激素。年处方患病率从2011年11.7%升至2015年12.5%,共配发922 026支,主要为高效价药物,73.1%由全科医生处方。
要点
- 约12%的法国普通人群每年至少被处方一次外用糖皮质激素。
- 处方主要由全科医生开具,皮肤科医生占比不足四分之一。
- 每年至少24支的高用量患者以男性、年长者更多,且药物效价更强。
核心结论
- 约12%的法国普通人群每年至少被处方一次外用糖皮质激素,处方主要来自全科医生。
研究设计与样本
- 基于法国EGB数据库(主医保系统覆盖人群的1/97随机抽样,约占总人口90%)的5年人群队列研究,纳入2011年1月1日至2015年12月31日所有被处方外用糖皮质激素的患者。
主要发现
- 5年研究期内EGB记录662 531人,其中220 345人(33.3%)至少一次被处方外用糖皮质激素。
- 外用糖皮质激素处方患病率从2011年11.7%规律上升至2015年12.5%。
- 共配发922 026支外用糖皮质激素,主要为高效价药物,73.1%由全科医生处方。
- 1713例(0.8%)患者在一个日历年内被处方至少24支,该组男性更多(P < 0.001)且年龄更大(P < 0.001)。
- 高用量患者获配的124 844支药物效价强于总体处方人群(P < 0.001),68.1%由全科医生处方。
临床怎么用
- 法国经验提示外用糖皮质激素处方广泛,全科医生是主要处方者,皮肤科医生占比不足四分之一。
- 对每年使用至少24支的高用量患者,需关注男性、年长者及高效价药物使用情况。
局限性
- 仅371例(21.7%)患者有处方原因记录,主要涉及银屑病、自身免疫性大疱性皮肤病和湿疹。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about the prescriptions of topical glucocorticoids in the general population. OBJECTIVES: To report an overall picture of topical glucocorticoid prescriptions in France. METHODS: This study used the Echantillon Généraliste de Bénéficiaires (EGB) database, a 1/97th random sampling of the French population covered by the main national healthcare insurance system (approximately 90% of the whole population). All patients prescribed topical glucocorticoids over a 5-year period (1 January 2011 to 31 December 2015) were identified using a specific code list for topical glucocorticoids. RESULTS: Over the 5-year study period, 662 531 individuals were recorded for at least 1 day in the EGB. Among them, 220 345 (33.3%) were prescribed at least once topical glucocorticoid. The prevalence of topical glucocorticoid prescription increased regularly from 2011 (11.7%) to 2015 (12.5%). A total of 922 026 tubes of topical glucocorticoids were dispensed, mainly high-potency glucocorticoids, and were mainly prescribed by general practitioners (73.1%). A total of 1713 (0.8%) patients were prescribed at least 24 tubes over a calendar year. These patients were more frequently men (P < 0.001) and older (P < 0.001) than the overall population of patients prescribed topical glucocorticoids. The 124 844 tubes prescribed to these patients had stronger potency than those prescribed to the overall population (P < 0.001) and were mostly prescribed by general practitioners (68.1%). The reasons for prescription were available for only 371 patients (21.7%) and were mainly psoriasis, auto-immune bullous dermatoses and eczema. CONCLUSION: About 12% of the French general population is prescribed topical glucocorticoids at least once each year. Most prescriptions are issued by general practitioners, dermatologists being the prescribers in less than one-quarter of cases.
引用
- El-Khoury M, Thay R, N'Diaye M, et al. Use of topical glucocorticoids: a population-based cohort study. J Eur Acad Dermatol Venereol. 2017. PMID: 28150352. doi:10.1111/jdv.14149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。